Main Article Content
handed out to community pharmacists and physicians. Pharmaceutical industry decision makers were enrolled in this study. Data were analyzed using the SPSS statistical software program version 10. 79.5% of pharmacists and 74% of physicians thought that TTSs eliminate variables due to gut absorption. 78.8% of pharmacists and 65.6% of physicians were in agreement
regarding the capacity ofÂ Â TSs to avoid first-pass metabolism. In this study, 83.3% of the physicians and 81.3% pharmacists
T still agree that TTSs may provide controlled release. 55.8% of pharmacists and only 26% of physicians believed that TTSs eliminate drug-plasma fluctuation. 56.8% of pharmacists and 63.5% of physicians agreed that TTSs can use drugs with low therapeutic indices. 81.3% of pharmacists and 85.4% of physicians believed that TTSs are not invasive and can be removed easily to stop drug administration. 81.3% of physicians and 89.1% of pharmacists thought that TTSs may irritate or sensitize the skin. Eighty-four percent of pharmacists and 75% of physicians recognize that TTSs should contain drugs that must be
stable and have correct physicochemical properties. The importance ofÂ Â TSs is understood and appreciated by Palestinian T health personnel. Pharmaceutical industries should pay more attention to the development and production ofÂ Â TSs due to T the valuable advantages of this therapeutic system.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Segal, Marian. Patches, Pumps and Timed Release: New Ways to Deliver
Drugs. Food and Drug Administration. http://www.fda.gov/bbs/topics/
consumer/CON00112.html. Retrieved on 2007;2:24.
â€œFDA approves scopolamine patch to prevent peri-operative nauseaâ€.
Food and Drug Administration. 1997;10-11.
Burris JF. The USA experience with the clonidine transdermal
therapeutic system. Clin Auton Res 1993;3:391-6.
Tanner T, Marks R. Delivering drugs by the transdermal route: review
and comment. Skin Res Technol 2008;14:249-60.
Cappelli C, Reale G, Marucci G, Clerico A. Transdermal fentanyl: A new
tool for pain therapy in pediatric oncology. Clin Ter 2008;159:257-60.
Finnin BC. Transdermal drug delivery: What to expect in the near future,
business briefing. Pharmatech 2003;192-3.
Kumar R, Philip A. Modified transdermal technologies: Breaking the barriers of drug permeation via the skin. Trop J Pharma Res 2007;6:633-44.
Langer R. Transdermal drug delivery: Past progress, current status, and
future prospects. Adv Drug Deliv Rev 2004;56:557-8.
Braun M, Cawello W, Boekens H, Horstmann R. Influence of
domperidone on pharmacokinetics, safety and tolerability of the
dopamine agonist rotigotine. Br J Clin Pharmacol 2009;67:209-15.
Hupfeld S, Gravem H. Tidsskr Nor Laegeforen. Transdermal therapeutic
systems for drug administration 2009;12:532-3.
Gordon MN, Muller CD, Sherman KA, Morgan DG, Azzaro AJ, Wecker L.
Oral versus transdermal selegiline: Antidepressant-like activity in rats.
Pharmacol Biochem Behav 1999;63:501-6.
Miyazaki T, Hanaoka K, Namiki A, Ogawa S, Kitajima T, Hosokawa T,
et al. Efficacy, safety and pharmacokinetic study of a novel fentanyl-
containing matrix transdermal patch system in Japanese patients with
cancer pain. Clin Drug Investig 2008;28:313-25.
Graziottin A. A review of transdermal hormonal contraception: Focus
on the ethinylestradiol/norelgestromin contraceptive patch. Treat
Berner B, John VA. Pharmacokinetic characterisation of transdermal
delivery systems. Clin Pharmacokinet 1994;26:121-34.
Chandrashekar NS, Shobha Rani RH. Physicochemical and
pharmacokinetic parameters in drug selection and loading for
transdermal drug delivery. Indian J Pharma Sci 2008;70:94-6.
Manna A, Ghosh I, Sen N, Thakur RS, Ghosh LK, Gupta BK. Statistical
optimization of transdermal drug delivery system of terbutaline sulfate
by factorial analysis. Boll Chim Farm 2000;139:34-40.
Benson HA. Transdermal drug delivery: Penetration enhancement
techniques. Curr Drug Deliv. 2005;2:23-33.
Cross SE, Robert S. Targeting local tissues by transdermal application:
Understanding drug physicochemical properties that best exploit
protein binding and blood flow effects. Drug Dev Res 1999;46:309-15.
Williams AC, Barry BW. Skin absorption enhancers. Crit Rev Ther Drug
Carrier Syst 1992;9:305-53.
Carmichael AJ, Foulds IS. Allergic contact dermatitis from transdermal
nitroglycerin. Contact Dermatitis 1989;21:113-4.
Wolf R, TÃ¼zÃ¼n B, TÃ¼zÃ¼n Y. Adverse skin reactions to the nicotine
transdermal system. Clin Dermatol. 1998;16:617-23.
Roche GamÃ³n E, de la Cuadra Oyanguren J, PÃ©rez Ferriols A, Fortea
Baixauli JM. Contact dermatitis from nitroglycerin in a transdermal
therapeutic system. Acta Derm Venereol 2006;86:544-5.
Kounis NG, Zavras GM, Papadaki PJ, Soufras GD, Poulos EA,
Goudevenos J, et al. Allergic reactions to local glyceryl trinitrate
administration. Br J Clin Pract 1996;50:437-9.
Zurawin RK, Ayensu-Coker L. Innovations in contraception: A review.
Clin Obstet Gynecol 2007;50:425-39.